SNYNF
Sanofi
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
93.45
▲ 2.92 (3.23%)
MARKET · —
Price
Open
93.45
Prev close
90.53
Day high
90.01
Day low
90.01
Volume
115
Market cap
$111.96B
P/E (TTM)
25.46
52W range
80.74 – 106.34
Trailing performance
Returnvs SPY
1W
+6.07%
+7.4%
1M
+5.86%
+2.1%
3M
+4.12%
+1.0%
6M
-1.67%
-12.7%
YTD
-3.96%
-16.2%
1Y
-8.38%
-28.4%
3Y
-9.28%
-83.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$111.96B
Enterprise value$129.55B
Revenue (TTM)$48.92B
Gross profit$35.93B
EBITDA$13.54B
Net income$3.94B
EPS (TTM)$3.67
Free cash flow$6.30B
Total cash$6.35B
Total debt$23.58B
Book value / share$66.47
Shares outstanding1.20B
Float1.08B
Short % of float—
Dividend yield5.18%
Beta (5Y)0.28
Valuation & profitability ratios
Trailing P/E25.46
Forward P/E10.10
PEG ratio30.36
Price / sales—
Price / book1.41
EV / revenue2.65
EV / EBITDA9.57
Gross margin73.45%
Operating margin21.03%
Profit margin8.09%
Return on equity5.71%
Return on assets5.09%
Debt / equity33.89
Current ratio0.99
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $43.63B | $41.08B | $43.07B | $43.00B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $7.81B | $5.74B | $5.40B | $6.72B |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $7.81B | $5.74B | $5.40B | $6.72B |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $13.17B | +5.9% |
| Next quarter | — | — | $12.49B | +10.5% |
| Current year | — | — | $47.59B | +9.1% |
| Next year | — | — | $50.70B | +6.5% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders10.31%
Held by institutions42.85%
Institutions holding854
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
123.56M
Total on file
Moving averages & technicals
SMA 10
88.66
+5.40% from price
SMA 20
87.38
+6.95% from price
SMA 50
86.68
+7.81% from price
SMA 100
88.39
+5.73% from price
SMA 200
91.72
+1.89% from price
EMA 12
88.99
+5.01% from price
EMA 26
87.80
+6.44% from price
EMA 50
87.45
+6.86% from price
RSI (14)
65.4
Neutral
MACD (12,26,9)
1.20
Hist 0.68
ATR (14)
1.70
1.82% of price
Realised vol 30D
40.0%
Annualised
Bollinger upper
93.14
20, 2σ
Bollinger lower
81.62
20, 2σ
50 / 200 cross
Death
86.68 vs 91.72
Trend bias
Above 200
+1.89%
Risk profile
Beta vs SPY
-0.12
Less volatile than market
Correlation to SPY
-0.04
Largely independent
Realised vol 30D
40.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-22.6%
Peak to trough
Max drawdown 5Y
-35.9%
Peak to trough
ATR 14
1.70
1.82% of price
Beta (reported)
0.28
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
NVAX Stock Alert: Biotechs Hit Post-Pandemic High on mRNA Cancer Breakthrough
Barchart · 1d ago
Making Drugs With AI: Biopharma Giants Gear Up For New Arena
Investor's Business Daily · 1d ago
Is Sanofi (ENXTPA:SAN) Reasonable After A 10% Three Year Slide?
Simply Wall St. · 3d ago
HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation
TMX Newsfile · 3d ago
Sanofi (ENXTPA:SAN) On TD Cowen Spotlight And The Case For A Higher Valuation
Simply Wall St. · 4d ago
European Equities Traded in the US as American Depositary Receipts Head Lower in Tuesday Trading
MT Newswires · 4d ago
AimwellBio Secures Proprietary Behavioral AI Portfolio Backed by Oxford Science and Sanofi Pilot; Inventor Dr. Chris A. Jones Joins Board of Advisors
ACCESS Newswire · 5d ago
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
MarketBeat · 6d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.